BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country. BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.

Last month, the Drugs Controller Gene ..Our aim is to ramp up the availability of successful treatment and coordinate manufacturing so that there is no scarcity of drugs to give to people fighting the disease," BDR Pharmaceuticals CMD Dharmesh Shah said in a statement.

The company thinks that by widening and deepening the identification and development of COVID-19 therapy options, this collaboration can address more unmet medical needs, he added.

The product would be priced competitively and will be available in  ..The Phase-II trial, which lasted from December 2020 to March 2021, enrolled 220 patients.

The medicine was discovered to speed up the recovery of COVID-19 patients in hospitals and to lessen the need for supplementary oxygen in COVID-19 patients. MSS DRR DRR